Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 8/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.46 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481290 | 1.00 | HASPIN (0.54) | HASPINGSK3BCLK1DAPK3PLK1 | |
| SCHEMBL2502319 | 0.80 | HASPIN (0.54) | HASPINGSK3BCLK1DAPK3PLK1 | |
| SCHEMBL1982292 | 0.80 | TSHR (0.60) | HASPINGSK3BCLK1DAPK3PLK1 | |
| SCHEMBL3589139 | 0.80 | HASPIN (0.54) | HASPINGSK3BCLK1DAPK3PLK1 | |
| SCHEMBL18935881 | 0.80 | HASPIN (0.54) | HASPINGSK3BCLK1DAPK3PLK1 | |
| SCHEMBL14423247 | 0.80 | HASPIN (0.54) | HASPINGSK3BCLK1DAPK3PLK1 | |
| Bromide SCHEMBL16238937 | 0.79 | HASPIN (0.52) | HASPINGSK3BCLK1DAPK3PLK1 | |
| SCHEMBL3609606 | 0.78 | HASPIN (0.56) | HASPINGSK3BCLK1DAPK3PLK1 | |
| SCHEMBL31179441 | 0.78 | HASPIN (0.51) | HASPINGSK3BCLK1DAPK3PLK1 | |
| SCHEMBL1982994 | 0.78 | HASPIN (0.51) | HASPINGSK3BCLK1DAPK3PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-10-17 | — | — | US | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | KAYOTHERA INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KAYOTHERA INC. (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117897370-A | Heterocyclic compounds and their use | 凯悦施那有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4326696-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kayothera Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022226383-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KAYOTHERA INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-2444395-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-102448941-A | Substituted isoquinoline derivatives | WESTERN THERAPEUTICS INST INC D | 2012-05-09 | — | — | CN | disclosed |
| EP-2444395-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2007109182-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | ALDH3A1, ALDH2, ALDH1A2 | HASPIN 1737/4885GSK3B 874/4885CLK1 2596/4885 |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | HASPIN 1013/4885GSK3B 121/4885CLK1 22/4885 |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | HASPIN 1351/4885GSK3B 1086/4885CLK1 2237/4885 |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | ALDH3A1, ALDH2, ALDH1A2 | HASPIN 1737/4885GSK3B 874/4885CLK1 2596/4885 |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, ALDH2, PDK1 | HASPIN 1336/4885GSK3B 805/4885CLK1 3371/4885 |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | HASPIN 1276/4885GSK3B 3694/4885CLK1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.